[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"furcation-defects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:furcation-defects":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,76,103,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652214","morphological-characteristics-of-mandibular-molar-furcation-involvement-and-efficacy-of-regenerative-surgical-treatment-100652214",false,"NCT07770256","Morphological Characteristics of Mandibular Molar Furcation Involvement and Efficacy of Regenerative Surgical Treatment","Morphological Characteristics of Furcation Involvement in Mandibular Molars and Efficacy of Regenerative Surgical Treatment: A Cross-Sectional and Interventional Trial","Inclusion Criteria:\n\n* Patients aged 18 years or older who signed the informed consent form.\n* Diagnosed with Stage III or Stage IV periodontitis according to the 2017 AAP\u002FEFP classification.\n* Completed non-surgical periodontal therapy with full-mouth plaque score (FMPS) and bleeding on probing (FMBS) \\\u003C= 20%.\n* Presence of at least one mandibular molar with Hamp Class II furcation involvement (horizontal bone loss \\> 3 mm without through-and-through communication).\n* Target tooth requirements:\n\n  * Probing pocket depth (PPD) \\>= 5 mm.\n  * Clinical attachment loss (CAL) \\>= 3 mm.\n  * Tooth mobility \\\u003C= Grade I (Miller index).\n  * Vital pulp or adequately filled root canal treatment without periapical radiolucency.\n  * Gingival margin positioned coronal to the furcation entrance.\n  * Intact tooth structure without root fractures or furcation caries.\n\nExclusion Criteria:\n\n* Uncontrolled systemic diseases (e.g., uncontrolled diabetes, hypertension, cardiovascular disease, severe osteoporosis).\n* Pregnant or lactating women.\n* Current smokers or individuals who quit smoking less than 6 months prior to enrollment.\n* Use of antibiotics, anti-inflammatory agents, or medications affecting bone metabolism (e.g., bisphosphonates, high-dose corticosteroids, anti-resorptive drugs) within the past 3 months.\n* Previous periodontal surgery at the evaluation site within the past 6 months.\n* Target teeth presenting with:\n\n  * Miller Grade II or Grade III tooth mobility.\n  * Severe bone destruction extending to the root apex.\n  * Metallic restorations (metal crowns, amalgam fillings, or large metallic posts) causing significant scatter\u002Fartifacts on CBCT scans.\n  * Fused roots or abnormal root anatomy.","ALL","18 Years",{"count":19,"type":20},98,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study consists of two components evaluating furcation involvement in mandibular molars among Stage III or Stage IV periodontitis patients. Component 1 is a cross-sectional study evaluating the prevalence and morphological characteristics of Hamp Class II furcation defects during initial screening. Component 2 is a randomized controlled clinical trial in 30 selected patients comparing the diagnostic accuracy of Cone Beam Computed Tomography (CBCT) against direct intra-operative clinical measurements, as well as evaluating the clinical and radiographic outcomes of regenerative periodontal surgery using Acellular Dermal Matrix (ADM) + Enamel Matrix Derivative (EMD) + Xenograft versus Autogenous Connective Tissue Graft (CTG) + EMD + Xenograft.",[26,27,28],"Periodontitis","Periodontitis (Stage 3)","Furcation Defects",[30,31,32,33,34],"Periodontal Regeneration","Connective Tissue Graft","Enamel Matrix Derivative","Acellular Dermal Matrix","Cone-Beam Computed Tomography","RECRUITING","2026-08-14",{"date":38,"type":39},"2026-08-18","ACTUAL",{"date":41,"type":39},"2026-05-02",{"date":43,"type":20},"2028-05",{"name":45,"class":46},"University of Medicine and Pharmacy at Ho Chi Minh City","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100651706","efficacy-of-prf-and-xenograft-in-treating-mandibular-molar-furcation-involvements-100651706","NCT07764029","Efficacy of PRF and Xenograft in Treating Mandibular Molar Furcation Involvements","Efficacy of Platelet-Rich Fibrin Combined With Xenograft in the Treatment of Mandibular Molar Furcation Involvements","Inclusion Criteria:\n\n* Patients over 18 years old\n* Patients diagnosed with periodontitis who have completed non-surgical treatment: scaling and root planing\n* Patients attending a follow-up visit at least 5 weeks after non-surgical treatment, demonstrating compliance and good oral hygiene cooperation\n* Presence of a mandibular molar with a Degree II furcation involvement according to Hamp (1975), presenting a residual periodontal pocket at the buccal site (PPD ≥ 5mm) after non-surgical treatment, and showing radiolucency in the furcation area on CBCT imaging\n* Plaque Index (PlI) \\\u003C 1 following non-surgical treatment\n* Width of keratinized gingiva ≥ 2mm\n* Teeth with furcation defects where gingival recession does not extend apically beyond the buccal furcation fornix (no supragingival furcation exposure)\n* Teeth without occlusal trauma, pulpal or periapical pathologies, and no combined periodontic-endodontic lesions\n* Degree II furcation involvement according to Hamp (1975) and Subclass A or B according to Tarnow and Fletcher (1984)\n* The defect is located apical to the interproximal alveolar bone crest on CBCT imaging\n\nExclusion Criteria:\n\n* Patients with systemic diseases affecting periodontal treatment outcomes, such as: diabetes mellitus, heart disease requiring anticoagulant therapy, blood disorders, immunodeficiency, etc\n* Pregnant or lactating patients\n* Patients who have used antibiotics or any other medications affecting periodontal treatment outcomes within the last 6 months\n* Patients who smoke tobacco.\n* Patients who have used aspirin or medications affecting blood coagulation within 2 weeks prior to the blood collection for PRF preparation\n* Patients with a history of allergy to local anesthetics\n* Defects associated with grade II tooth mobility that has not been splinted, or grade III tooth mobility according to Miller (2014)",{"count":56,"type":20},22,[23],"The purpose of this randomized controlled clinical trial is to compare the effectiveness of advanced platelet-rich fibrin (A-PRF+) combined with xenograft versus a collagen membrane combined with xenograft in the treatment of degree II furcation involvements in mandibular first molars. Adult patients with periodontitis will randomly receive either the A-PRF+ treatment or the collagen membrane treatment during periodontal flap surgery. The study will evaluate clinical periodontal healing, bone regeneration using 3D imaging (CBCT), patient comfort (pain levels and satisfaction), and changes in the TWEAK biomarker in gingival crevicular fluid over a 6-month period.",[26,28],[61,62,63,64,65,66,67,68],"A-PRF plus","A-PRF+","Xenograft","Mandibular Molar","Guided Tissue Regeneration","TWEAK","biomarker","collagen membrane","2026-08-12",{"date":36,"type":39},{"date":72,"type":39},"2026-06-25",{"date":74,"type":20},"2027-06-30",{"name":45,"class":46},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":47},"100642867","effect-of-mobile-health-on-plaque-control-efficacy-in-molars-with-furcation-involvement-100642867","NCT07642895","Effect of Mobile Health on Plaque Control Efficacy in Molars With Furcation Involvement","Effect of Mobile Health on Plaque Control Efficacy in Molars With Furcation Involvement: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Systemically healthy individuals with clinically visible furcation entrance in mandibular molars in Stage III periodontitis\n* Horizontal bone loss extent ≥ 3mm29 and vertical bone loss ( Subclass A\u002FB)30\n* Access to mobile phone\n\nExclusion Criteria:\n\n* Presence of systemic diseases that could influence the outcome of periodontal therapy (Diabetes mellitus, Hypertension)\n* Smoking\u002Falcohol consumption\n* Teeth with Grade II\u002FIII mobility\n* History of periodontal treatment or antibiotic therapy in the last 6 months\n* Non-vital and carious teeth to be restored\n* Physically and mentally impaired patients\n* Furcation involvement with cervical enamel projections, enamel pearls and bifurcation ridges","55 Years",{"count":85,"type":20},76,[23],"Furcation involvement (FI) refers to a condition in which the progression of the periodontal disease process invades the bifurcation and trifurcation of multirooted teeth. Furcation involvement, present a clinical challenge due to its anatomic complexity and reduced access for adequate plaque control which may leads to further periodontal breakdown. Consequently, maintenance of adequate oral hygiene is critical in these sites.\n\nIt has been shown that poor oral hygiene, together with the persistence of periodontal risk factors, leads to further disease progression, treatment failure, and disease recurrence.\n\nMobile health can serve as a valuable adjunctive approach by aiding in behavioral reinforcement through real-time reminders. With widespread mobile phone usage in India, mHealth interventions are feasible. The role of mHealth in management of furcation involved sites has still not been explored. Therefore, this randomized controlled clinical trial aims to evaluate the effectiveness of mobile health reinforcements in improving plaque control efficacy at in furcation involved sites following non-surgical periodontal therapy, with the potential to enhance patient compliance and prevent further disease progression and disease recurrence.",[28],[90,91,92],"FURCATION","FURCATION INVOLVEMENT","MHEALTH","NOT_YET_RECRUITING","2026-06-09",{"date":96,"type":39},"2026-06-11",{"date":98,"type":20},"2026-06",{"date":100,"type":20},"2027-12",{"name":102,"class":46},"Postgraduate Institute of Dental Sciences Rohtak",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":47},"100568710","a-chitosan-brush-and-enamel-matrix-derivative-for-non-surgical-treatment-of-furcations-100568710","NCT06684769","A Chitosan Brush and Enamel Matrix Derivative for Non-surgical Treatment of Furcations","Non-surgical Treatment of Mandibular and Maxillary Molar Furcations With a Chitosan Brush With Adjunct Enamel Matrix Derivative- a Split-mouth Randomized Clinical Trial","Inclusion criteria:\n\n1. The patient is 18 years of age or older\n2. The patient does not have any systemic diseases that may affect the results of the study\n3. The patient has a plaque index of 20% or less at the study entry\n4. The patient has a history of severe localized or generalized periodontitis (stage III or IV)\n5. Completed the first and second steps of periodontal treatment (According to Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline) (Sanz M. et al.)\n6. Buccal and\u002For lingual Class 2A and\u002For 2B furcation involvement (FI) defects on both sides of the Mandibular first and\u002For second molars after completing the first and second steps of periodontal treatment.\n7. Buccal Class 2A and\u002For 2B furcation involvement (FI) defects on both sides of the maxillary first and\u002For second molars after completion of the first and second step of periodontal treatment if furcation involvement on the palatal side (mesiopalatal and distopalatal) does not exceed Class 1.\n8. Psychological appropriateness\n9. Consents to all follow-up visits\n\nExclusion Criteria:\n\n1. Patients who have systemic diseases that may affect the results of the study\n2. Use of medications that may affect study results (anti-osteoporotic drugs, statins, corticosteroids, anticoagulants)\n3. Patients who use calcium channel blockers, cyclosporine A or antiepileptic drugs if there are clinically visible hyperplastic changes in the gingival margin.\n4. Patients who have received any type of systemic antibiotics in the last six months prior to the start of the study and patients starting antibiotics during the study\n5. Patients requiring antibiotic premedication prior to periodontal treatment\n6. Oncological disease\n7. Chemotherapy and\u002For radiotherapy (active or history)\n8. Pregnancy and breastfeeding\n9. Any condition or current treatment which, in the opinion of the investigator and\u002For consulting physician, may present an unreasonable risk\n10. Psychoemotional disorders and depression\n11. Use of antipsychotic medication or antidepressants\n12. Lack of patient motivation to undertake adequate dental care at home or complete periodontal treatment, patients residing outside Latvia\n13. Molars with combined endodontic-periodontal lesions, active endodontic infection\n14. Prosthetic factors for molars not allowing clinical measurements\n15. Huge restoration or amalgam fillings that could potentially cause fractures or furcation involvement\n16. Enamel pearls or filling or crown margins\n17. Decay or root resorption\n18. Tooth mobility degree 3\n19. Molars in which the gingival margin is positioned apically from the entrance into the furcation area\n20. Clinical attachment level and or pockets mesial and distal to the furcation involvement defect of 6 or more mm\n21. Strong vomiting reflex that would prevent adequate periodontal treatment\n22. People close to the study subjects, work colleagues, relatives, etc.",{"count":111,"type":20},40,[23],"Patients diagnosed with stage III or IV periodontitis who exhibit mandibular first or second molars with Class II, Subclass A, or B buccal and\u002For lingual mandibular furcation defects (horizontal probing depth of ≥ 3 mm ) will be recruited.\n\nPatients diagnosed with stage III or IV periodontitis who exhibit maxillary first or second molars with Class II, Subclass A, or B buccal furcation defects (horizontal probing depth of ≥ 3 mm ) if furcation involvement on the palatal side (mesiopalatal and distopalatal) does not exceed Class 1 will be recruited.\n\nThis study will be a prospective, randomized, single-blinded, controlled clinical trial with a split-mouth design.\n\nPatients will be recruited from the clinics of the Riga Stradiņš University Institute of Stomatology of Riga, Latvia.\n\nBefore the baseline treatment, all patients who meet the inclusion criteria will be given detailed oral hygiene instructions and motivation.\n\nPatients' furcation defects in each quadrant will be randomly allocated at a 1:1 ratio to either the application of Oscillating Chitosan Brush with Enamel Matrix Derivatives (test group) or Oscillating Chitosan Brush alone (control group).\n\nNon-surgical periodontal treatment of furcation defects on the test side will be performed through the application of Oscillating Chitosan Brush with Enamel Matrix Derivatives and on the control side with Oscillating Chitosan Brush alone.\n\nThe re-evaluation of periodontal status will be performed 12 weeks following the baseline treatment.\n\nBiofilm samples and gingival crevicular fluid (GCF) samples will be taken at the baseline and at 4 weeks.",[115,28,116,117],"Periodontitis, Adult","Furcation of Root of Tooth","Periodontitis Complex","2025-08-31",{"date":120,"type":39},"2025-09-08",{"date":122,"type":39},"2024-11-15",{"date":124,"type":20},"2026-11",{"name":126,"class":46},"Riga Stradins University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":47},"100536859","use-of-a-bone-substitute-material-in-the-surgical-therapy-of-furcation-defects-100536859","NCT06270303","Use of a Bone Substitute Material in the Surgical Therapy of Furcation Defects","The Use of a Bone Substitute Material in the Surgical Therapy of Furcation Defects - a Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\nPatients should present with at least one surgically accessible molar (in tooth position 6 or 7) diagnosed with a single furcation defect degree II (at any aspect).\n\nFollowing initial periodontal therapy, teeth to be included should present with one site with furcation defect degree II in combination with:\n\n* Bleeding on probing\n* Probing pocket depth of ≥6 mm\n* Soft tissue coverage of the furcation entrance Patients should present with a full mouth plaque score ≤25%.\n\nExclusion Criteria:\n\n* Multiple deep furcation defects (degree II - III) at the same tooth\n* Vertical attachment loss \\>50% at aspects not facing the furcation defect\n* Defects presenting with apico-marginal communication\n* Intake of systemic antibiotics within 6 months\n* Systemic conditions\u002Fmedication impeding surgical intervention (e.g. uncontrolled diabetes, immunosuppressive medication)",{"count":135,"type":20},200,[23],"The aim of this randomized clinical trial is to evaluate the potential benefit of the use of a bone substitute material in the treatment of furcation degree II-involved molars. The main question it aims to answer is: What is the benefit of the adjunctive use of a bone substitute material in the surgical treatment of furcation degree II-involved molars when compared to open-flap debridement alone?\n\n200 patients with ≥1 molar presenting with a furcation defect degree II will be included and randomized to either control (open-flap debridement) or test treatment (open-flap debridement + bone substitute material). The primary outcome of the study is furcation closure defined as absence of clinically detectable furcation involvement degree \\>I. Secondary outcomes include changes in bleeding on probing, probing depth, vertical and horizontal attachment levels, soft tissue level, marginal bone level, need for surgical retreatment, tooth loss, patient-reported outcomes and adverse events. A composite outcome based on furcation closure (degree ≤I) in combination with shallow probing depth (≤5 mm) and absence of bleeding on probing will also be evaluated.",[26,28],[140,141,142],"Surgical therapy","Reconstructive","Randomized controlled trial","2025-08-20",{"date":145,"type":39},"2025-08-21",{"date":147,"type":39},"2025-03-27",{"date":149,"type":20},"2037-03-01",{"name":151,"class":46},"Göteborg University"]